Casdin Capital’s MaxCyte MXCT Stock Holding History

Casdin Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,890,000	Closed	-$5.9M	–	40
2023 Q3	$5.9M	Sell	1,890,000 -2,825,000	-60%	-$11.4M	0.65%	26
2023 Q2	$21.6M	Sell	4,715,000 -210,000	-4%	-$965K	1.89%	18
2023 Q1	$24.4M	Sell	4,925,000 -4,580,000	-48%	-$22.6M	2.01%	16
2022 Q4	$51.9M	Sell	9,505,000 -1,230,786	-11%	-$7.55M	4.02%	8
2022 Q3	$69.8M	Sell	10,735,786 -3,235,548	-23%	-$18M	4.58%	9
2022 Q2	$66.1M	Hold	13,971,334	–	–	5.59%	5
2022 Q1	$97.7M	Hold	13,971,334	–	–	4.38%	8
2021 Q4	$142M	Hold	13,971,334	–	–	4.01%	10
2021 Q3	$171M	Buy	+13,971,334	New	+$211M	4.25%	7

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Casdin Capital's MXCT Position: Q4 2023 in Review

Casdin Capital sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 1,890,000 shares — an estimated $5.9M sold.

Casdin Capital first reported a position in MXCT in Q3 2021 and held it in 9 quarters. The position peaked at $171M in Q3 2021. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

Casdin Capital reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
Casdin Capital sold 1,890,000 MaxCyte shares in Q4 2023, an estimated $5.9M.
Casdin Capital first reported a position in MaxCyte in Q3 2021 and held it in 9 quarters.
Casdin Capital's MaxCyte position peaked at $171M in Q3 2021.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Casdin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.